LGVN News and Press, Longeveron Inc. From 12/21/23

MIAMI, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (...

2023-12-20 12:21:53 ET More on Longeveron Longeveron GAAP EPS of -$0.28 misses by $0.04, revenue of $0.2M misses by $0.07M Longeveron to implement ~$4M registered direct offering of shares Seeking Alpha’s Quant Rating on Longeveron For further details ...

Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-Related Frailty, is releasing new clinical and biomarker ...

New clinical data showed that Lomecel-B™ improved cognitive function in multiple measures in a dose-response fashion Caregiver ratings documented improved quality of life in Lomecel-B™ treated patients MRI Biomarker study data showed that Lomecel-B™ ...

Wearable smart devices that track daily circadian rest-activity rhythms may allow for the detection of frailty-related health risks in seniors more than six years before the problems occur. A new study from Harvard-affiliated Brigham and Women’s Hospital has found that smart trackers c...

Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, in October announced topline results from its phase 2a CLEAR MIND trial, investigating Lomecel-B(TM) for the treatment of mild Alzheimer ...

Alzheimer’s is a progressive illness that often begins with mild loss of memory and confusion. This type of dementia involves parts of the brain that control memory, thought and language. Patients in very severe decline often have difficulty carrying out daily activities, which may incl...

Longeveron recently released topline results from its Phase 2a trial evaluating Lomecel-B(TM) as a potential treatment for mild AD The study met its primary safety endpoint across all four study groups and showed positive and statistically significant results in secondary endpoint involving the...

Toxoplasma gondii (T. gondii) is a single-cell parasite that can cause severe physical and mental conditions. This parasite is known to trigger risky behavior in hosts. The most common way for an individual to be exposed to this parasite is when disposing of cat litter. This is because while the...

2023-11-15 17:02:17 ET Longeveron ( NASDAQ: LGVN ) files to sell 5.02M shares of class A common stock for holders. This preliminary prospectus is not an offer to sell. SEC Filing For further details see: Longeveron files to sell 5.02M shares of class A c...